Metabolic Brain Disease

, Volume 30, Issue 1, pp 205–213 | Cite as

The neuroprotective potential of sinapic acid in the 6-hydroxydopamine-induced hemi-parkinsonian rat

  • Kobra Zare
  • Akram Eidi
  • Mehrdad Roghani
  • Ali Haeri Rohani
Research Article


Parkinson’s disease (PD) is a neurodegenerative movement disorder due to selective loss of dopaminergic neurons of mesencephalic substantia nigra pars compacta (SNC) with debilitating motor symptoms. Current treatments for PD afford symptomatic relief with no prevention of disease progression. Due to the antioxidant and neuroprotective potential of sinapic acid, this study was conducted to evaluate whether this agent could be of benefit in an experimental model of early PD in rat. Unilateral intrastriatal 6-hydroxydopamine (6-OHDA)-lesioned rats were pretreated p.o. with sinapic acid at doses of 10 or 20 mg/kg. One week after surgery, apomorphine caused significant contralateral rotations, a significant reduction in the number of Nissl-stained and tyrosine hydroxylase (TH)-positive neurons and a significant increase of iron reactivity on the left side of SNC. Meanwhile, malondialdehyde (MDA) and nitrite levels in midbrain homogenate significantly increased and activity of superoxide dismutase (SOD) significantly reduced in the 6-OHDA-lesioned group. In addition, sinapic acid at a dose of 20 mg/kg significantly improved turning behavior, prevented loss of SNC dopaminergic neurons, lowered iron reactivity, and attenuated level of MDA and nitrite. These results indicate the neuroprotective potential of sinapic acid against 6-OHDA neurotoxicity that is partially due to the attenuation of oxidative stress and possibly lowering nigral iron level.


Sinapic acid Parkinson’s disease 6-hydroxydopamine Neuroprotection Oxidative stress 



This work was the results of a Ph. D. thesis project financially funded and supported by Science and Research Branch of the Islamic Azad University (Tehran, Iran) in 2012. The authors would also like to appreciate Fariba Ansari and Maryam Sharayely for their great technical assistance.

Conflict of interest

There is no conflict of interest.


  1. Andringa G, van Oosten RV, Unger W, Hafmans TG, Veening J, Stoof JC, Cools AR (2000) Systemic administration of the propargylamine CGP 3466B prevents behavioural and morphological deficits in rats with 6-hydroxydopamine-induced lesions in the substantia nigra. Eur J Neurosci 12:3033–3043PubMedCrossRefGoogle Scholar
  2. Baluchnejadmojarad T, Roghani M (2011) Chronic epigallocatechin-3-gallate ameliorates learning and memory deficits in diabetic rats via modulation of nitric oxide and oxidative stress. Behav Brain Res 224:305–310PubMedCrossRefGoogle Scholar
  3. Baluchnejadmojarad T, Roghani M, Mafakheri M (2010) Neuroprotective effect of silymarin in 6-hydroxydopamine hemi-parkinsonian rat: involvement of estrogen receptors and oxidative stress. Neurosci Lett 480:206–210PubMedCrossRefGoogle Scholar
  4. Bargiotas P, Konitsiotis S (2013) Levodopa-induced dyskinesias in Parkinson’s disease: emerging treatments. Neuropsychiatr Dis Treat 9:1605–1617PubMedCentralPubMedGoogle Scholar
  5. Bisaglia M, Filograna R, Beltramini M, Bubacco L (2014) Are dopamine derivatives implicated in the pathogenesis of Parkinson’s disease? Ageing Res Rev 13C:107–114CrossRefGoogle Scholar
  6. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248–254PubMedCrossRefGoogle Scholar
  7. Chakraborty S, Bornhorst J, Nguyen TT, Aschner M (2013) Oxidative stress mechanisms underlying Parkinson’s disease-associated neurodegeneration in C. elegans. Int J Mol Sci 14:23103–23128PubMedCentralPubMedCrossRefGoogle Scholar
  8. Chen S, Le W (2006) Neuroprotective therapy in Parkinson disease. Am J Ther 13:445–457PubMedCrossRefGoogle Scholar
  9. Datla KP, Zbarsky V, Rai D, Parkar S, Osakabe N, Aruoma OI, Dexter DT (2007) Short-term supplementation with plant extracts rich in flavonoids protect nigrostriatal dopaminergic neurons in a rat model of Parkinson’s disease. J Am Coll Nutr 26:341–349PubMedCrossRefGoogle Scholar
  10. De Araujo DP, Lobato Rde F, Cavalcanti JR, Sampaio LR, Araujo PV, Silva MC, Neves KR, Fonteles MM, Sousa FC, Vasconcelos SM (2011) The contributions of antioxidant activity of lipoic acid in reducing neurogenerative progression of Parkinson’s disease: a review. Int J Neurosci 121:51–57PubMedCrossRefGoogle Scholar
  11. Fahn S (2003) Description of Parkinson’s disease as a clinical syndrome. Ann N Y Acad Sci 991:1–14PubMedCrossRefGoogle Scholar
  12. Foley P, Riederer P (2000) Influence of neurotoxins and oxidative stress on the onset and progression of Parkinson’s disease. J Neurol 247(Suppl 2):II82–94PubMedGoogle Scholar
  13. Halliday GM, McCann H (2010) The progression of pathology in Parkinson’s disease. Ann N Y Acad Sci 1184:188–195PubMedCrossRefGoogle Scholar
  14. Hattori N (2004) Etiology and pathogenesis of Parkinson’s disease: from mitochondrial dysfunctions to familial Parkinson’s disease. Rinsho Shinkeigaku 44:241–262PubMedGoogle Scholar
  15. Jalali-Nadoushan M, Roghani M (2013) Alpha-lipoic acid protects against 6-hydroxydopamine-induced neurotoxicity in a rat model of hemi-parkinsonism. Brain Res 1505:68–74PubMedCrossRefGoogle Scholar
  16. Le W (2014) Role of iron in UPS impairment model of Parkinson’s disease. Parkinsonism Relat Disord 20(Suppl 1):S158–161PubMedCrossRefGoogle Scholar
  17. Lee HE, Kim DH, Park SJ, Kim JM, Lee YW, Jung JM, Lee CH, Hong JG, Liu X, Cai M, Park KJ, Jang DS, Ryu JH (2012) Neuroprotective effect of sinapic acid in a mouse model of amyloid beta (1–42) protein-induced Alzheimer’s disease. Pharmacol Biochem Behav 103:260–266PubMedCrossRefGoogle Scholar
  18. Lotharius J, Brundin P (2002) Pathogenesis of Parkinson’s disease: dopamine, vesicles and alpha-synuclein. Nat Rev Neurosci 3:932–942PubMedCrossRefGoogle Scholar
  19. Pari L, Mohamed Jalaludeen A (2011) Protective role of sinapic acid against arsenic: induced toxicity in rats. Chem Biol Interact 194:40–47PubMedCrossRefGoogle Scholar
  20. Paxinos G, Watson C (1986) The rat brain in stereotaxic coordinates, 2nd edn. Academic, San DiegoGoogle Scholar
  21. Qiao HY, Dahiya JP, Classen HL (2008) Nutritional and physiological effects of dietary sinapic acid (4-hydroxy-3,5-dimethoxy-cinnamic acid) in broiler chickens and its metabolism in the digestive tract. Poult Sci 87:719–726PubMedCrossRefGoogle Scholar
  22. Roghani M, Niknam A, Jalali-Nadoushan MR, Kiasalari Z, Khalili M, Baluchnejadmojarad T (2010) Oral pelargonidin exerts dose-dependent neuroprotection in 6-hydroxydopamine rat model of hemi-parkinsonism. Brain Res Bull 82:279–283PubMedCrossRefGoogle Scholar
  23. Roy SJ, Mainzen Prince PS (2013) Protective effects of sinapic acid on cardiac hypertrophy, dyslipidaemia and altered electrocardiogram in isoproterenol-induced myocardial infarcted rats. Eur J Pharmacol 699:213–218PubMedCrossRefGoogle Scholar
  24. Roy SJ, Stanely Mainzen Prince P (2012) Protective effects of sinapic acid on lysosomal dysfunction in isoproterenol induced myocardial infarcted rats. Food Chem Toxicol 50:3984–3989PubMedCrossRefGoogle Scholar
  25. Schapira AH, Jenner P (2011) Etiology and pathogenesis of Parkinson’s disease. Mov Disord 26:1049–1055PubMedCrossRefGoogle Scholar
  26. Schober A (2004) Classic toxin-induced animal models of Parkinson’s disease: 6-OHDA and MPTP. Cell Tissue Res 318:215–224PubMedCrossRefGoogle Scholar
  27. Shapiro RM, Glick SD, Camarota NA (1987) A two-population model of rat rotational behavior: effects of unilateral nigrostriatal 6-hydroxydopamine on striatal neurochemistry and amphetamine-induced rotation. Brain Res 426:323–331PubMedCrossRefGoogle Scholar
  28. Shin DS, Kim KW, Chung HY, Yoon S, Moon JO (2013) Effect of sinapic acid against carbon tetrachloride-induced acute hepatic injury in rats. Arch Pharm Res 36:626–633PubMedCrossRefGoogle Scholar
  29. Smith Y, Wichmann T, Factor SA, DeLong MR (2012) Parkinson’s disease therapeutics: new developments and challenges since the introduction of levodopa. Neuropsychopharmacology 37:213–246PubMedCentralPubMedCrossRefGoogle Scholar
  30. Sriram K, O’Callaghan JP (2007) Divergent roles for tumor necrosis factor-alpha in the brain. J Neuroimmune Pharmacol 2:140–153PubMedCrossRefGoogle Scholar
  31. Tapias V, Cannon JR, Greenamyre JT (2013) Pomegranate juice exacerbates oxidative stress and nigrostriatal degeneration in Parkinson’s disease. Neurobiol Aging 35:1162–1176PubMedCrossRefGoogle Scholar
  32. Von Bohlen und Halbach O, Schober A, Krieglstein K (2004) Genes, proteins, and neurotoxins involved in Parkinson’s disease. Prog Neurobiol 73:151–177CrossRefGoogle Scholar
  33. Wang J, Xu H, Jiang H, Du X, Sun P, Xie J (2012) Neurorescue effect of rosmarinic acid on 6-hydroxydopamine-lesioned nigral dopamine neurons in rat model of Parkinson’s disease. J Mol Neurosci 47:113–119PubMedCrossRefGoogle Scholar
  34. Weinreb O, Mandel S, Youdim MB, Amit T (2013) Targeting dysregulation of brain iron homeostasis in Parkinson’s disease by iron chelators. Free Radic Biol Med 62:52–64PubMedCrossRefGoogle Scholar
  35. Yun KJ, Koh DJ, Kim SH, Park SJ, Ryu JH, Kim DG, Lee JY, Lee KT (2008) Anti-inflammatory effects of sinapic acid through the suppression of inducible nitric oxide synthase, cyclooxygase-2, and proinflammatory cytokines expressions via nuclear factor-kappaB inactivation. J Agric Food Chem 56:10265–10272PubMedCrossRefGoogle Scholar
  36. Zhou ZD, Refai FS, Xie SP, Ng SH, Chan CH, Ho PG, Zhang XD, Lim TM, Tan EK (2013) Mutant PINK1 upregulates tyrosine hydroxylase and dopamine levels, leading to vulnerability of dopaminergic neurons. Free Radic Biol Med 68C:220–233Google Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Department of Biology, Science and Research BranchIslamic Azad UniversityTehranIran
  2. 2.Neurophysiology Research CenterShahed UniversityTehranIran

Personalised recommendations